Skip to main content

Glotzbach Lab

The Glotzbach Lab

Aortic tissue sample

The Glotzbach Lab at the University of Utah is focused on understanding the biological and clinical mechanisms underlying cardiovascular disease, particularly aortic pathology and structural heart disease. Our projects aim to understand the genetic, molecular, and biomechanical factors that contribute to aortic aneurysms, dissections, and valve disease, and how these mechanisms can inform improved surgical and transcatheter therapies.

His team uses a combination of clinical research, translational studies, and collaborative investigations integrating human patient data, imaging, and genetic analysis to better understand disease progression and optimize treatment strategies.

Research

The Glotzbach lab focuses on understanding the genetic, structural, and clinical mechanisms underlying cardiovascular diseases and developing improved therapeutic and surgical strategies for aortic and valvular disease.

Aortic Disease and Genetic Mechanisms 

  • The lab investigates aortic aneurysms and dissections, including the role of genetic conditions such as connective tissue disorders (e.g., Marfan syndrome) and bicuspid aortic valve disease.
  • This work is important because identifying genetic and structural drivers of disease can improve risk prediction and guide earlier, more effective intervention. 

Structural Heart Disease & Advanced Therapies

  • Research includes outcomes and optimization of surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR).
  • The lab participates in clinical trials comparing treatment approaches, aiming to refine decision-making and improve patient outcomes in complex cardiovascular disease. 

PRINCIPAL INVESTIGATOR

Jason P. Glotzbach, MD, earned his undergraduate degree in History from Princeton University and his MD from the Tulane University School of Medicine. He completed general surgery training at the University of North Carolina and cardiothoracic surgery training at Columbia University. 

  • He joined the University of Utah in 2016 and is currently an Assistant Professor of Surgery in the Division of Cardiothoracic Surgery. 
  • Clinically, he is the Co-Director of the Aortic Disease Program, where he treats patients with aortic aneurysms, dissections, and complex aortic pathology using both open and endovascular techniques. 
  • He specializes in minimally invasive cardiac surgery, aortic reconstruction, and structural heart interventions, including transcatheter valve therapies (TAVR). 
  • Dr. Glotzbach is actively involved in clinical and translational research, including studies on the genetic basis of aortic disease and leadership as a principal investigator in clinical trials evaluating valve replacement strategies. 

RESEARCH TEAM

OR tissue sample

Working with Jason Glotzbach, MD, is a multidisciplinary team of surgeons, researchers, and clinical collaborators within cardiothoracic surgery and cardiovascular research programs.

Clinical researchers and collaborators 

  • Team members contribute to clinical trials, outcomes research, imaging analysis, and translational studies related to aortic and valvular disease. 
  • The lab collaborates closely with cardiologists, geneticists, and surgeons to integrate bench-to-bedside approaches in cardiovascular care. 

SPOTLIGHT ON RESEARCH

GETTING TO THE HEART OF IT

Decoding the Genetics of Aortic Disease

You could be carrying a genetic risk for a deadly aortic disease and have no idea.

Find out how Dr. Jason Glotzbach and his team are using one of the only databases in the world linking family trees to medical records, not only to identify risk before it’s too late, but to build a future, brick-by-brick, where generations of families could receive personalized care based on their unique genetic risk.

jason Glotzbach with voice wave
Jason Glotzbach, MD
  • This transcript was created from an audio recording of Voices of Surgery. Spoken conversation doesn't always translate perfectly to the page, so small edits have been made here for readability and clarity. If you're able to listen, we'd encourage it: the tone, the pauses, the moments of laughter, all come through best in the original audio. Subscribe wherever you get your podcasts to catch every episode.

    The opinions expressed by our hosts and guests are their own and don't necessarily reflect the official views of the University of Utah or the Department of Surgery.

     

    Introduction

    Jason Glotzbach: I think we're starting to understand that genetics and heritability play a role in many diseases that can be a nuanced contribution, and that many people have genetic susceptibility to disease that don't know about it. And I think the more information that we can bring to individual patient decisions, the better off the care team and each individual patient will be in terms of navigating their kind of health problems.

    Interviewer: Welcome to Voices of Surgery. I'm Niki Tonks, and I'm Keslie Ta'afua. One podcast. Many voices shaping the future of surgery. I'm Niki, and today I'm joined again by Dr. Jason Glotzbach, a cardiothoracic surgeon and translational scientist, to explore one of University of Utah's most extraordinary research resources, the Utah Population Database, and how it's helping researchers answer questions that simply can't be answered anywhere else. Thanks for joining me.

    Jason Glotzbach: Absolutely. Thanks for having me.

     

    Something That Should Not Be True

    Interviewer: Tell me something that should not be true, but is.

    Jason Glotzbach: I think we're starting to understand that genetics and heritability play a role in many diseases that can be a nuanced contribution, and that many people have genetic susceptibility to disease that don't know about it. And I think the more information that we can bring to individual patient decisions, the better off the care team and each individual patient will be in terms of navigating their kind of health problems.

    Interviewer: Knowing is the first step, right? If we don't know if it's genetically inherited, it's hard to answer the questions or solve the problems.

    Jason Glotzbach: Absolutely.

     

    What Is the Utah Population Database?

    Interviewer: So in our previous conversation about aortic disease, you mentioned using population data to better understand inherited conditions. And I would really love to pick up on that thread. Tell me exactly what is the Utah Population Database and why is it such an extraordinary resource here?

    Jason Glotzbach: The Utah Population Database is basically a link between genealogical data, so family trees, pedigree information, and the medical record. In the database we have individuals and families from Utah with their entire family history going back several generations. The genius of the Population Database is taking that genealogical record and linking it to the medical record, which allows us to use diagnoses or medical conditions or procedures to understand the distribution of medical problems, disease conditions, or risks of needing procedures or other things, how those risks and how those medical problems or diagnoses distribute across a family across multiple generations. Which then allows us to ask the question, is there a familial contribution or a genetic contribution to the etiology or the development or the progression of a certain disease?

     

    Why It Matters for Aortic Disease

    Interviewer: So how does this influence your work in cardiovascular surgery?

    Jason Glotzbach: It's very relevant to aortic disease because a large portion, especially thoracic aortic disease, does have a heritable component. And it's a very complex genetic picture. Some genetic diseases such as sickle cell anemia or cystic fibrosis or Marfan syndrome, which is an [unclear] syndrome. Those diseases are what we call Mendelian, meaning there's one gene that has a variant or a mutation that then causes the disease. And we've figured out a lot of those diseases over the last 200 years, many people have been working on this, and we understand a lot of how the genetics work in those diseases and therefore how to guide treatment. Many more conditions are what we call polygenic, meaning that multiple genes are involved in the pathogenesis or the risk or the susceptibility to the disease. And many of the variants or mutations in those many genes are not binary. So the picture becomes much more complicated. These are things like height or personality traits or all these things that are genetically influenced. But it's not just one gene that's on or off or working or not working. And so as it relates to aortic disease, we know that heritability is important. And if we could understand an individual patient's genetic risk for developing an aortic aneurysm or an aortic dissection, that would help us guide therapy to be more or less aggressive or use different medications or offer surgery at different times. And we really just don't understand that well enough to use it clinically yet.

     

    Looking for Patterns Across Families

    Jason Glotzbach: So the Population Database asks us or allows us to ask the question, what is the familial contribution for a given disease? And this goes back to the uniqueness of the resource, the Population Database having multiple generations of genealogical data linked to the medical record is very powerful because you can see a disease that clusters in a family across multiple generations. If you just look at a group of patients that present to a clinical practice with the disease, it's very difficult to tease out the family history of all those patients because many people don't know their family history or we don't have access to that information. So using that tool, we can see, oh, in this family, this disease is a little bit more common. And then we can focus in on trying to figure out why that disease is more common, or what genetic variants are contributing to that disease being more common in that family.

     

    Why Genetics Matter in Aortic Disease

    Interviewer: So for those who may not have heard the other podcast that we just did, can you talk a little bit about these aortic diseases and why it's so important to understand the genetic side of it? You mentioned that some of them are really hard to know up front, and exactly when to do the surgery or when to intervene. It's kind of maybe a little bit of a balance and a guess right now.

    Jason Glotzbach: That's exactly correct. So we talk about aortic disease as a broad category. And that includes aortic dilation, which is called aortic aneurysm, where the aorta grows larger than it should be in diameter and or length. And that disease is on a kind of continuum with the dreaded aortic complication called aortic dissection. That's when the aortic wall splits apart, and the pressurized blood from inside the artery works its way inside the aortic wall. That's a surgical or medical emergency, very high mortality risk. And so we know that aneurysm disease and aortic dissection disease does tend to run in families sometimes. There are some cases where it appears out of the blue and no family members have been involved. And there are some families where many family members across multiple generations have had this disease. And so we ultimately would love to be able to use the genetic risk to include in the decision making for the treatment plan for a given patient. And right now we use things like aortic size, aortic growth rate, other kind of comorbidities or risk factors like smoking and diabetes and hypertension. But those are fairly imprecise metrics. And one of the main treatments for thoracic aortic disease is cardiac surgery. Basically is open heart surgery to replace a section of the aorta as it's become aneurysmal, to try to prevent aortic dissection. That's a big operation. There is, unfortunately, some complications that come along with that sometimes, and putting people through that major surgery is a big step. And we'd like ideally to only put people through the surgery for an aneurysm who are at significant risk for an aortic dissection. And we know that many people who have aneurysms probably would never have a dissection. And there are people that have dissections that had a relatively small aneurysm that hadn't met the threshold yet for surgery. So size and growth rate are important, but it's not the only consideration. So if we could understand someone's genetic predisposition and say, well, this person's aorta probably is at higher risk than someone else because of their genetic history or their genetic predisposition, then we might offer a surgical therapy earlier or more aggressive medical therapy. We're not there yet. This is all very hypothetical at this point in our day to day clinical practice, we really are using other things other than genetics at this point.

     

    Precision Medicine and Personalized Care

    Interviewer: So talking about the future, really, if you understand the genetics behind it and you know where someone may have a small marker, where somebody else may have a big and the dissection occurs somewhere in between. But if you have that genetic information, then possibly you can provide individualized care. Talk to me about this precision medicine and maybe the personalized medicine, and how the database and generational research is going to help us get to that point.

    Jason Glotzbach: This is the direction that medical care in general is headed more. We're seeing this a lot in cancer therapy. For example, when I went through medical school 20 years ago, we barely touched on the genetics of cancer. And now it's routine that if someone gets a diagnosis, they're getting the genetic panel. And that helps guide therapy. And so precision medicine or personalized medicine, those terms are relatively synonymous. That implies using additional information, usually genetic information, looking at someone's genome sequence to determine their risk for a certain disease, and to use that risk on a personalized or individualized basis to guide therapy. So whether choosing a medication regimen or choosing a surgical procedure or timing of those things, if we can understand more precisely an individual's risk, and then we can act on that to provide more nuanced clinical decision making, then that should provide better care for the individual patient.

     

    Where the Research Stands Today

    Interviewer: So you're currently using this database to try to understand this. Where are you at in this process? I'm assuming it's really lengthy.

    Jason Glotzbach: It's a good question. The database is a very powerful research tool. So the database resource coupled with genomic basic science research is allowing us to unlock or understand the genomic landscape for these diseases. So fortunately, the cost of whole genome sequencing has come way down in the last 15 years. And it's now realistic and feasible to do a whole genome screen on multiple people in a cost effective way. And so we use the Population Database to identify large trends across the whole population. We've done that, and we published that work a couple of years ago looking at bicuspid aortic valve disease, aortic aneurysm, aortic dissection and familial risk. And we showed in the Population Database that if you have one of those diagnoses, then the risk in your first degree, second degree relatives and even first cousins is elevated to have one of those diagnoses and actually have a higher mortality from one of those diagnoses. And so that was the first step. So we've identified that there is a signal in this population that some of these diseases tend to run in families. The next step is to try to drill down on the genetic details of what's going on. So we're actively recruiting patients and family members from the database, as well as our clinical practice, to perform whole genome sequencing on individuals where we know their phenotype, meaning we know if they have the disease or not, and then we can use that genome sequencing information to compare affected individuals with non affected individuals, which allows us to see where are the differences in the genome. And if we can see a pattern that a certain variant, also called a mutation, in a certain gene is more likely to be present in someone who has the condition, then that suggests that that gene variant might be driving that genetic risk. And then the third step will be looking forward with a kind of prospective study to identify people that have the genome signature that we think is associated with the disease. And then we watch them over time to see if they developed the disease. And that will kind of validate this approach. So this is a very long term project, very kind of resource intensive and people intensive. It's not just me doing this. This is a huge group of collaborators here at the University of Utah and Intermountain Health across the whole state. Really, we need experts in, you know, clinical experts like myself, but also geneticists, bioinformatics experts, population scientists. We are all working together on this, using our collective expertise to try to sort through this very complex problem.

     

    Why This Takes So Long

    Interviewer: How far are you into phase two? How long will it go and where do you think phase three begins?

    Jason Glotzbach: Did the NIH put you up to this question?

    Interviewer: I would love to get some funding for you.

    Jason Glotzbach: Yeah, that's a great question. More funding. I'm going to hedge a little bit. It's very difficult to say if or how long it will take to be successful. I would like to think that we're on a path that will yield some results within the next 3 to 5 years.

    Interviewer: Oh, wow.

    Jason Glotzbach: It's a little bit unknown or uncertain how quickly we can move from genomic associations and what we call genome-wide studies looking at the entire genome across many hundreds of patients or thousands of patients. We're talking about billions of data points. And so the computational analysis involved and understanding those data are, you can imagine, quite complex. We often will find many false positives. So things that look associated. But then with further analysis, further testing, they turned out to be kind of random noise in the data. And so all of us have many variants across our genomes that really don't have functional ramifications. And that's just the way genetics works, is that it's a very messy, noisy environment. And to understand causal effect of a genome variant to a disease is quite a difficult scientific evidence process. 

    Interviewer: You have a leap. 

    Jason Glotzbach: You have to really be diligent and kind of systematic and methodical about finding those links and proving that those links are real before it can be clinically actionable. The worst thing would be to say we think these genes are associated, and then start making clinical decisions on patients who have those variants. And then it turns out that they weren't relevant or they weren't as important as we thought. And so we have to be careful. I think that this project, this effort, this kind of concept, this is a 10 to 20 year process. And we may get lucky and it might go a little faster, but I think that in our lifetimes we will probably get there. It may not be my lab. It might be my, you know, successors and other collaborators that figure this out after I've retired. I think it's very important that we just keep moving forward with this work.

     

    The Role of Artificial Intelligence

    Interviewer: Do you feel like AI and this generation of massive machine learning will impact any of this?

    Jason Glotzbach: I think it's going to be somewhere between very helpful and completely revolutionary. And I don't know exactly where we're going to fall in that spectrum. We're using machine learning techniques now in our research to help tease out these large database and these large data sets that I mentioned. The bioinformatics tools are rapidly evolving to where we can understand large data sets and utilize the machine learning, artificial intelligence type of approaches to make sense of very complex data. And so we're absolutely using that now. I think as these tools continue to evolve, and a lot of my collaborators are on the leading edge of this work is to develop and understand and implement these novel tools and computing power. Computing speed is getting faster and cheaper. And I'm cautiously optimistic that we are going to make a difference in aortic disease care or cardiovascular care. And these techniques will be applied across many different disease processes and different areas of medical care.

     

    Why Clinical Scientists Matter

    Interviewer: Yeah, I mean, it's a really exciting time. And I think sometimes folks don't really sit back and look, if we're not intimately involved in the process and don't see the years and years, decades of work happening before you've gotten to this point and you know where you're at and the leap that it takes and it takes not just the people and the minds to do it, but it absolutely takes funding. And it's so incredibly important to keep funding into these types of things, to keep the work that's happened happening and to not stop where we're at and to make it continue.

    Jason Glotzbach: I couldn't agree more. And I think from my perspective as a cardiovascular aortic surgeon, I think that it's very important that clinical experts are involved in the research because I am not a genetics expert, I'm not a bioinformatics expert, I'm not a population scientist. But my clinical understanding of the clinical problem and the need for our patients helps to kind of clarify the research questions and to keep the research moving efficiently towards a clinically relevant outcome. And so my goal with my career is to kind of stay in the game and try to help provide my expertise or my perspective to help the kind of expert scientists ask the right questions and then interpret the results. And I think if we can do that and we can consistently keep this work funded and keep this work moving forward, that we will contribute something. And for me, it's very motivating. I think, you know, this is why I want to be at the University of Utah. This is why I wouldn't trade my challenges for any other type of practice or career environment. And it's very exciting to work on this stuff.

    Interviewer: Making a difference on all fronts. Right? Direct patient care and the future of direct patient care. And I can absolutely see why it's so important to have the clinician here, because I can imagine there are an infinite number of questions that a scientist could have that lead you down this rabbit hole, and they may find a discovery, but it may not directly lead to patient care. So that's why it's so critically important.

     

    Collaboration Is the Key

    Interviewer: And how do you manage having both the clinical practice and the scientific practice?

    Jason Glotzbach: I've learned to ask for and embrace a lot of help from my colleagues. What I've learned in my career is that I have much more effectiveness and ability to do things if I lean on others and work with others. And so I have a unique skill set and experience that I try to bring to these projects. And if everyone else does the same thing, then our overlapped expertise is stronger than any of us alone. And I'm 100% convinced of that. And I see that every day in my clinical work, and I see consistently in my scientific work that the best projects, the best outcomes are when we're working together. And that's, you know, one of the coolest things about the University of Utah is that the culture of this place, the institutional focus on collaboration, really lends itself to this kind of work, both on the clinical and on the scientific investigative side.

    Interviewer: Yes, definitely a team sport. We hear over and over and over, having done 30 something interviews, it's everything is a collaboration. Nothing happens in a silo. You know, you can only do the small bit of your part, do it really well, but you have to have the other people surrounding you. 

    Jason Glotzbach: Yeah.

     

    Why Patients Matter in Research

    Interviewer: So many of these patients whose information contributes to research or who are in clinical studies now, they might not ever see the research come to fruition. What would you want them to know about the impact they have and they're making?

    Jason Glotzbach: Yeah, and I think that's true of so many things that we all do. And I think my favorite analogy is the medieval cathedral builders, who were the stonemasons who were laying stone for foundation of a cathedral that wouldn't be completed for 200 years, and they would never see the finished product. But that one little piece that they were doing that day, they did it because they knew that it mattered, and it was part of something bigger than themselves. And so I think all of us collectively are trying to work together to make this a better set of information, a better understanding of these diseases. And I think that the patient involvement is crucial. And I think that many people, when we present this work, are very excited and very happy to be a part of it in any small way, even if they know that their personal care won't be impacted because they're in the middle of getting care right now. And this is, you know, in the future we won't be using this knowledge, but people still understand the value of this, and they want to contribute so that others in the future, and often it's their family members, you know, their grandkids might benefit if they happen to be susceptible in the same way. That gives people a lot of comfort and a lot of motivation to contribute to this effort.

    Interviewer: Yeah, patient engagement is definitely a beautiful gift when folks are, you know, outside themselves and maybe even in a really difficult time themselves right now, knowing that it may not help them, but it may in the future. 

    Jason Glotzbach: And I think it provides meaning in someone's individual journey or their struggle with the disease to say, well, I'm going through this, but I can contribute to something that's bigger than me or to someone else, and that provides a lot of meaning and helps, I think, with kind of current individual hardship to say, I'm going through this right now, this is really hard. I'm faced with this disease or this surgery or whatever, but by being a part of this research study or contributing what I can, I might help somebody else. And that, I think, is a very fulfilling, rewarding realization for patients and for clinicians and scientists. I mean, that's why we're all doing this. And I think keeping that in mind is very important because it is such a slow, complex, large effort. And we're not going to figure this out tomorrow. But if we keep doing this day to day, then at some point we will have moved the needle, which is pretty awesome.

    Interviewer: Right. If all of us bricklayers just do our one row, then eventually just keep laying the stone and eventually you'll have a cathedral

    Jason Glotzbach: Right!

     

    What Do You Hope Will Be True Someday?

    Interviewer: What do you hope will be true someday because of the work you're doing today?

    Jason Glotzbach: I would love it if someone came to the office of a cardiac surgeon with an aortic aneurysm. And we say, well, we're going to run your whole genome sequence, and we're going to run it through our database. And that database algorithm is going to spit out a precise genetic risk based on your individual genome. And then we'll factor that in with all the other information, like the size of your aorta and your blood pressure and other medicines and other things. And we'll give you a very precisely tailored treatment plan just for you to the best that we can. And we can't do that right now. Right now, we say my best guess, based on a thousand people that had this disease and we looked at a bunch of sizes of aorta, is our best guess, is that you need this, and it's the best we can do right now. But I think we can do a lot better in the future.

    Interviewer: What does that mean for their mother, their father, their sister, their children, their grandchildren?

    Jason Glotzbach: I think it extends to the whole family. So we can say to the patient in front of us, your genome is this, which means we're going to do this treatment plan. Now, we'd like to go test your siblings, your children, your cousins, whomever in your family we have access to. And then we'll help determine their treatment plan. Ideally, if we can do this on a large enough scale, with enough accuracy and enough precision, then I think that we can drastically reduce the occurrence in the incidence of aortic dissection. Aortic aneurysms are dangerous because they lead to dissection. If we can figure out who's at risk and we can do things to prevent those dissections, then we will have saved a lot of lives and prevented a lot of morbidity. And so we mentioned in our last conversation, I would love to be the old surgeon sitting around telling stories about when we used to take care of acute aortic dissection because no one ever sees it anymore, because that disease has been largely eradicated.

     

    Closing Thoughts

    Interviewer: Yeah, that's a good looking future. It'd be awesome. Thanks for all the work you're doing. Thank you for sitting down again with me today.

    Jason Glotzbach: Happy to do it. 

    Interviewer: You know, hopefully we can lend our hand in getting out this message and this hope. 

    Jason Glotzbach: I think anyone who's listening and would like to learn more or certainly contribute to this effort, please do reach out to our team. We're always happy to have new collaborators and new partners in this work.

    Interviewer: Absolutely. My hope from this is that word gets out and we get some more support for your team.

    Jason Glotzbach: Absolutely. Well, thanks, Niki. I appreciate the opportunity.

    Interviewer: Yeah. Thank you.

Contact Us

LAB CONTACT

Email: Jason.glotzbach@hsc.utah.edu 
Address: 30 N Mario Capecchi Dr 4N145, Salt Lake City, UT 84112 

CLINICAL TRIALS

Email: margaret.carlson@hsc.utah.edu
Address: 30 N Mario Capecchi Dr 4N145, Salt Lake City, UT 84112